BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Formann E, Stauber R, Denk DM, Jessner W, Zollner G, Munda-Steindl P, Gangl A, Ferenci P. Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin. Am J Gastroenterol 2004;99:873-7. [PMID: 15128353 DOI: 10.1111/j.1572-0241.2004.30372.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Piekarska A, Jozefowicz-korczynska M, Wojcik K, Berkan E. Sudden hearing loss in chronic hepatitis C patient suffering from Turner syndrome, treated with pegylated interferon and ribavirin: Hipoacusia súbita en un paciente con síndrome de Turner y hepatitis crónica C tratado con interferón pegilado y ribavirina. International Journal of Audiology 2009;46:345-50. [DOI: 10.1080/14992020701261413] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
2 Sharifian MR, Kamandi S, Sima HR, Zaringhalam MA, Bakhshaee M. INF- α and ototoxicity. Biomed Res Int 2013;2013:295327. [PMID: 23984336 DOI: 10.1155/2013/295327] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
3 Little C, Cosetti MK. A Narrative Review of Pharmacologic Treatments for COVID-19: Safety Considerations and Ototoxicity. Laryngoscope 2021;131:1626-32. [PMID: 33491234 DOI: 10.1002/lary.29424] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
4 Mendes-Corrêa MC, Bittar RS, Salmito N, Oiticica J. Pegylated interferon/ribavirin-associated sudden hearing loss in a patient with chronic hepatitis C in Brazil. Braz J Infect Dis 2011;15:87-9. [PMID: 21412597 DOI: 10.1016/s1413-8670(11)70147-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
5 Eser Karlidag G, Karlidag T, Demirdag K, Keles E. The effects of pegylated interferon/lamivudine therapy on auditory functions in patients with chronic hepatitis B. Auris Nasus Larynx 2011;38:312-8. [PMID: 21216118 DOI: 10.1016/j.anl.2010.10.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Zittoon RF, Madian YT, Alhennawi DEM, Nadeem HS. Cochlear Changes Caused by Peginterferon α-2b. J Interferon Cytokine Res 2018;38:311-6. [PMID: 30016180 DOI: 10.1089/jir.2018.0012] [Reference Citation Analysis]
7 Le V, Bader T, Fazili J. A case of hearing loss associated with pegylated interferon and ribavirin treatment ameliorated by prednisone. Nat Rev Gastroenterol Hepatol 2009;6:57-60. [DOI: 10.1038/ncpgasthep1317] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
8 Elloumi H, Houissa F, Hadj NB, Gargouri D, Romani M, Kharrat J, Ghorbel A. Sudden hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment. World J Gastroenterol 2007; 13(40): 5411-5412 [PMID: 17879419 DOI: 10.3748/wjg.v13.i40.5411] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
9 Gozdas HT, Karabay O. Reversible bilateral ototoxicity in a patient with chronic hepatitis B during peginterferon alpha-2a treatment. Indian J Pharmacol 2015;47:121-2. [PMID: 25821325 DOI: 10.4103/0253-7613.150377] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
10 Loftis JM, Matthews AM, Hauser P. Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management. Drugs. 2006;66:155-174. [PMID: 16451091 DOI: 10.2165/00003495-200666020-00003] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 3.6] [Reference Citation Analysis]
11 Tanaka M, Hasegawa S, Nakao S, Shimada K, Mukai R, Matsumoto K, Nakamura M. Analysis of drug-induced hearing loss by using a spontaneous reporting system database. PLoS One 2019;14:e0217951. [PMID: 31593579 DOI: 10.1371/journal.pone.0217951] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
12 Ferenci P. Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future. Expert Opin Drug Saf. 2011;10:529-544. [PMID: 21345149 DOI: 10.1517/14740338.2011.555079] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
13 Ciorba A, Corazzi V, Skarżyński PH, Skarżyńska MB, Bianchini C, Pelucchi S, Hatzopoulos S. Don't forget ototoxicity during the SARS-CoV-2 (Covid-19) pandemic! Int J Immunopathol Pharmacol 2020;34:2058738420941754. [PMID: 32649262 DOI: 10.1177/2058738420941754] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
14 Casale M, Mazzarelli C, Vespasiani Gentilucci U, Potena M, Pappacena M, Faiella F, Galati G, Salvinelli F, Picardi A. Distortion-product otoacoustic emissions: a useful test for monitoring ototoxicity induced by pegylated interferon and ribavirin treatment in patients with chronic hepatitis C. Int J Immunopathol Pharmacol 2012;25:551-6. [PMID: 22697091 DOI: 10.1177/039463201202500229] [Reference Citation Analysis]
15 Wong VK, Cheong-Lee C, Ford JAE, Yoshida EM. Acute sensorineural hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment: Outcome after resumption of therapy. World J Gastroenterol 2005; 11(34): 5392-5393 [PMID: 16149154 DOI: 10.3748/wjg.v11.i34.5392] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
16 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol. 2016;22:76-139. [PMID: 27044763 DOI: 10.3350/cmh.2016.22.1.76] [Cited by in Crossref: 42] [Cited by in F6Publishing: 52] [Article Influence: 7.0] [Reference Citation Analysis]
17 Pompili M, Pizzolante F, Larocca LM, Covino M, Rapaccini GL, Gasbarrini G. Ischaemic jejunal vasculitis during treatment with pegylated interferon-alpha 2b and ribavirin for hepatitis C virus related cirrhosis. Dig Liver Dis 2006;38:352-4. [PMID: 16169782 DOI: 10.1016/j.dld.2005.07.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
18 Khiani V, Kelly T, Shibli A, Jensen D, Mohanty SR. Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon α 2a therapy for chronic hepatitis C virus infection. World J Gastroenterol 2008; 14(2): 318-321 [PMID: 18186575 DOI: 10.3748/wjg.14.318] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
19 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol 2014;20:89-136. [PMID: 25032178 DOI: 10.3350/cmh.2014.20.2.89] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
20 Johnson K, Sargent LA, Galizio C, Ubogu EE. Interferon-α-2b/ribavirin-induced vestibulocochlear toxicity with dysautonomia in a chronic hepatitis C patient: . European Journal of Gastroenterology & Hepatology 2008;20:1110-4. [DOI: 10.1097/meg.0b013e3282f8e583] [Cited by in Crossref: 10] [Article Influence: 0.7] [Reference Citation Analysis]
21 Jain S, Midha V, Sood A. Unilateral hearing loss due to pegylated interferon-α2b and ribavirin therapy. Indian J Gastroenterol 2011;30:239-40. [DOI: 10.1007/s12664-011-0126-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
22 Schreiber BE, Agrup C, Haskard DO, Luxon LM. Sudden sensorineural hearing loss. Lancet. 2010;375:1203-1211. [PMID: 20362815 DOI: 10.1016/s0140-6736(09)62071-7] [Cited by in Crossref: 248] [Cited by in F6Publishing: 79] [Article Influence: 20.7] [Reference Citation Analysis]
23 Torres-Odio S, Lei Y, Gispert S, Maletzko A, Key J, Menissy SS, Wittig I, Auburger G, West AP. Loss of Mitochondrial Protease CLPP Activates Type I IFN Responses through the Mitochondrial DNA-cGAS-STING Signaling Axis. J Immunol 2021;206:1890-900. [PMID: 33731338 DOI: 10.4049/jimmunol.2001016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
24 Ferenci P, Formann E, Laferl H, Gschwantler M, Hackl F, Brunner H, Hubmann R, Datz C, Stauber R, Steindl-Munda P. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection. J Hepatol. 2006;44:275-282. [PMID: 16338019 DOI: 10.1016/j.jhep.2005.09.015] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 2.7] [Reference Citation Analysis]
25 Calvaruso V, Mazza M, Almasio PL. Pegylated-interferon-α(2a) in clinical practice: how to manage patients suffering from side effects. Expert Opin Drug Saf 2011;10:429-35. [PMID: 21323500 DOI: 10.1517/14740338.2011.559161] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
26 Shin MK, Kim TH, Ju K, Ha CY, Min HJ, Jung WT, Lee OJ. A case of sudden-onset hearing loss in a patient treated with peginterferon α-2b and ribavirin for chronic hepatitis C. Korean J Hepatol 2009;15:370. [DOI: 10.3350/kjhep.2009.15.3.370] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]